2,5-Dichloropyridine → Tert-butyl 3-(5-chloro-2-pyridinyl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate
Reaction equation
[CH:1]12[N:8]([C:9]([O:11][C:12]([CH3:15])([CH3:14])[CH3:13])=[O:10])[CH:5]([CH2:6][CH2:7]1)[CH2:4][NH:3][CH2:2]2.Cl[C:17]1[CH:22]=[CH:21][C:20]([Cl:23])=[CH:19][N:18]=1>>[Cl:23][C:20]1[CH:21]=[CH:22][C:17]([N:3]2[CH2:4][CH:5]3[N:8]([C:9]([O:11][C:12]([CH3:15])([CH3:14])[CH3:13])=[O:10])[CH:1]([CH2:7][CH2:6]3)[CH2:2]2)=[N:18][CH:19]=1Participants
3
Procedure
tert-Butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate, prepared as described in (J. Med. Chem., (1998) 41, 674), and 2,5-dichloropyridine were processed as described in Example 10A to provide the title compound.
Sources & evidence
- ORD record
- ord-8a0a06e05262405fa3465d877be9bc2e
- Source dataset
- uspto-grants-2007_09
- Patent number
- US07265115B2
Reaction notes
Loading…